Seres Therapeutics
MCRB
70 hedge funds and large institutions have $143M invested in Seres Therapeutics in 2018 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 21 increasing their positions, 27 reducing their positions, and 7 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.04% less ownership
Funds ownership: 3.92% → 3.88% (-0.04%)
3% less funds holding
Funds holding: 72 → 70 (-2)
22% less repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 27
29% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 7
41% less capital invested
Capital invested by funds: $243M → $143M (-$99.7M)
97% less call options, than puts
Call options by funds: $4K | Put options by funds: $124K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$551K |
| 2 |
Renaissance Technologies
New York
|
+$338K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$225K |
| 4 |
Russell Investments Group
London,
United Kingdom
|
+$155K |
| 5 |
Two Sigma Investments
New York
|
+$126K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$1.67M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.25M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$217K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$206K |
| 5 |
BlackRock
New York
|
-$173K |
MCRB Hedge Fund Activity: Q4 2018 in Review
70 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in Seres Therapeutics (MCRB) for Q4 2018, worth a combined $143M — down 41% from $243M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of MCRB and 5 opened new positions — a net loss of 2 holders — while 27 trimmed existing stakes and 21 added.
The largest buyer was ARK Investment Management, adding an estimated $551K. The largest seller was Rock Springs Capital Management, exiting entirely with an estimated $1.67M sold.
- 70 institutional investors held Seres Therapeutics (MCRB) as of Q4 2018, down from 72 in Q3 2018.
- Funds reported $143M of Seres Therapeutics stock for Q4 2018, down 41% quarter-over-quarter.
- 5 funds opened new Seres Therapeutics positions in Q4 2018 and 7 closed out, a net change of -2 holders.
- The largest Seres Therapeutics buyer in Q4 2018 was ARK Investment Management, an estimated $551K added.
- The largest Seres Therapeutics seller in Q4 2018 was Rock Springs Capital Management, an estimated $1.67M sold.
Based on aggregated 13F filings for Q4 2018.